Search results
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 13 hours agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 14 hours agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 17 hours agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
J.P. Morgan downgrades Metagenomi over Moderna deal termination (NASDAQ:MGX)
Seeking Alpha· 10 hours agoJ.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent...
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via Yahoo Finance· 17 hours agoModerna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was ...
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Zacks via Yahoo Finance· 6 days agoModerna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 21 hours agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Moderna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall By Investing.com
Investing.com· 16 hours agoModerna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barrier
Guru Focus· 10 hours agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Moderna Quarterly Sales Beat Expectations but Plummet From Previous Year
US News & World Report· 17 hours agoSales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations ...